MET and Alzheimer disease: The study complements recent clinical literature reporting reduced MET protein levels in AD patient's brain and the posited beneficial effects of HGF/MET activation in AD therapeutics (Sharma, 2010; Hua et al., 2022) and further supports the view that HGF/MET signaling is neurotrophic and neuroprotective.